NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER
Gauri, Anju Goyal, Jitender Singh, Puneet Sudan, Sachin Kumar Sharma. Genetics and Molecular Research, 2026-06-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
One of the biggest health issues of the twenty-first century is Alzheimer's disease (AD), which is the most prevalent cause of dementia. With an estimated 40 million affected worldwide, the number is expected to increase significantly as the population ages, resulting in significant medical, social, and financial problems. Common neuropathological alterations that contribute to cognitive decline and functional impairment include amyloid-β (Aβ) plaque accumulation, neurofibrillary tangles made of hyperphosphorylated tau protein, synaptic dysfunction, and progressive neuronal loss. The exact cause of AD is still unknown despite decades of research, involving a complex interaction of lifestyle, environmental, and genetic factors. The chance of developing the condition is greatly increased by the apolipoprotein E (APOE) ε4 allele, mutations in APP, PSEN1, and PSEN2, and modifiable variables such cardiovascular diseases, traumatic brain injury, and lifestyle choices. Memantine, an NMDA receptor antagonist, and cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are examples of current pharmaceutical treatments that provide symptomatic relief without changing the course of the disease. Disease-modifying monoclonal antibodies that target Aβ, such as aducanumab and lecanemab, have recently raised cautious optimism, despite ongoing concerns about accessibility, safety, and efficacy. The need for a better understanding of AD pathophysiology and the conversion of basic science into useful clinical interventions is underscored by the growing emphasis on novel therapeutic approaches, such as gene-based interventions, neuroprotective approaches, and lifestyle changes. This review highlights new avenues for therapy development while giving a broad overview of the genesis, pathophysiology, and current therapeutic landscape of AD.
What this study adds
Evidence grade: Low
This review describes existing drugs like memantine and cholinesterase inhibitors that only relieve symptoms without changing the course of the disease. It notes that newer anti-amyloid antibodies such as aducanumab and lecanemab have raised cautious optimism but that concerns about accessibility and safety remain.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gauri, Goyal, A., Singh, J., Sudan, P., & Sharma, S. K. (2026). NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER. Genetics and Molecular Research. https://doi.org/10.4238/0fganh12
Vancouver
Gauri, Goyal A, Singh J, Sudan P, Sharma SK. NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER. Genetics and Molecular Research. 2026. doi:10.4238/0fganh12.
BibTeX
@article{gauri2026-f13bd11e,
author = {Gauri and Goyal, Anju and Singh, Jitender and Sudan, Puneet and Sharma, Sachin Kumar},
title = {{NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER}},
journal = {Genetics and Molecular Research},
year = {2026},
doi = {10.4238/0fganh12},
url = {https://doi.org/10.4238/0fganh12}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- With an estimated 40 million affected worldwide, the number is expected to increase significantly as the population ages, resulting in significant medical, social, and financial problems.
Why it matters
This review describes existing drugs like memantine and cholinesterase inhibitors that only relieve symptoms without changing the course of the disease. It notes that newer anti-amyloid antibodies such as aducanumab and lecanemab have raised cautious optimism but that concerns about accessibility and safety remain.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Genetics and Molecular Research) |
| Journal's citation record | 0 / 4 | Genetics and Molecular Research: journal h-index 71 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Sachin Kumar Sharma holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Rayat Bahra University: institution h-index 66 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Genetics from nearby years
Also in Genetics
198 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.